Novavax Inc. shares fell successful the extended league Thursday aft the biotech’s wider-than-expected nonaccomplishment connected the 4th overshadowed affirmative results for its COVID-19 vaccine booster.
Novavax NVAX, +5.54% shares fell 9% aft hours, pursuing a 5.5% summation successful the regular league to adjacent astatine $236.20.
The institution reported a second-quarter nonaccomplishment of $352.3 million, oregon $4.75 a share, compared with a nonaccomplishment of $17.5 million, oregon 30 cents a share, successful the year-ago period.
Revenue soared to $298 cardinal from $35.5 cardinal successful the year-ago 4th due to the fact that of services performed for the U.S. authorities and nether Coalition for Epidemic Preparedness Innovations agreements.
Analysts surveyed by FactSet, however, had forecast a nonaccomplishment of $3.63 a stock connected gross of $387.9 million.
The institution besides announced its COVID-19 vaccine booster fixed astatine six months aft an archetypal two-dose regimen accrued virus-fighting antibodies by 4 times, and by six times for those that fought the delta variant, according to results from a caller study.
Novavax said it filed with regulators successful India, Indonesia, and the Philippines to person an exigency usage support for its NVX-CoV2373 vaccine.
“We presumption these submissions arsenic the archetypal of galore filings to come, which volition let NVX-CoV2373 to beryllium made disposable astatine a planetary scale,” said Stanley Erck, Novavax president and main executive, successful a statement. “We proceed to spot the circulation of caller variants and inequitable entree to vaccine globally, demanding that we bring our COVID-19 vaccine to marketplace arsenic swiftly arsenic possible.”
/etf_analysis_proshares_ultrapro_nasdaq_biotech__ss-5bfc3af846e0fb0051c1e7d5.jpg)
English (US) ·